Vilazodone


SSRI + 5-HT1A partial agonist

A dual-mechanism antidepressant combining SSRI activity with 5-HT1A partial agonism intended to accelerate clinical response.

Abstract

Vilazodone (5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide; CAS 163521-12-8; molecular formula C26H27N5O2; molecular weight 441.53) is an SSRI plus 5-HT1A partial agonist developed at Merck KGaA and Forest Pharmaceuticals, approved by the FDA in 2011 under the trade name Viibryd. SERT affinity is approximately 0.1 nM; 5-HT1A affinity is approximately 0.2 nM (intrinsic activity approximately 70 percent), producing partial agonism at the autoreceptor. The dual mechanism was designed to bypass the autoreceptor desensitization period that delays SSRI response: by directly activating 5-HT1A receptors while blocking SERT, vilazodone aims to produce faster clinical effect. Real-world clinical trials have shown modest response acceleration. Plasma half-life is approximately 25 hours; metabolism is via CYP3A4 (primary). Approved for major depressive disorder. The compound is administered with food, which doubles bioavailability compared to fasted dosing. Used as a reference compound for 5-HT1A partial agonist plus SSRI pharmacology.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph